Regeneron Pharmaceuticals Stock News

There have been relatively few big winners among pharma stocks so far in the 2020s. One big pharma stock stands out as the clear leader by roughly tripling over the last nearly four years.

Regeneron Pharmaceuticals and Intellia Therapeutics have expanded their research collaboration to develop additional CRISPR-based gene editing therapies focused on neurological and muscular diseases,

Regeneron's share price has climbed by more than 100% over five years and is trading near its record high. The company sells a variety of products across indications and has a solid pipeline that coul

TARRYTOWN, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2023 financial and operating results on Thursda

It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASD

Regeneron's sales growth rate has been struggling over the past year. Revenue from its top-selling drug, Eylea, fell 7% in the most recent quarter.

Regeneron Pharmaceuticals, Inc. is a pharmaceutical company headquartered in Tarrytown that has played a key role in the fight against COVID-19. Regeneron's revenue for the second quarter of 2023 was

Regeneron Pharmaceuticals Inc.'s REGN, +0.74% agreement with the federal government to limit the list price of any new COVID monoclonal antibody commercialized as a result of their public-private part

Regeneron stock (NASDAQ: REGN) has seen a 6% rise in a month, compared to a 1% fall for the broader S&P500 index.

Regeneron Pharmaceuticals Inc. REGN, +0.66% said late Friday that Chief Financial Officer Robert E. Landry will retire in February, and Christopher Fenimore, the pharma company's current head of accou

Vertex and Regeneron have delivered solid financial results and stock market performance. Both biotechs have exciting pipelines that should produce key new approvals or label expansions.

Regeneron (REGN) gains 13% in a month on the FDA's approval of a higher dose of Eylea and other positive updates.

The oncology treatment market has been experiencing significant growth lately. Companies like Regeneron Pharmaceuticals (REGN), Merck & Co. (MRK), Novartis (NVS) and AstraZeneca (AZN) have made meanin

Regeneron's latest regulatory approval comes at an opportune time. The company's current lineup should continue generating growing sales.

TARRYTOWN, N.Y., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: